Management of Impaired Renal Function and Hyperglycemia

Assessment and Classification

The American College of Physicians recommends classifying a patient with an eGFR of 47 mL/min/1.73m² as having Stage 3a CKD, which is mildly to moderately decreased kidney function 1, 2

The American Diabetes Association recommends using metformin with caution in patients with an eGFR >45 mL/min/1.73m², as it can be used safely with careful monitoring 1, 2
The National Kidney Foundation recommends adding an SGLT2 inhibitor for patients with an eGFR ≥30 mL/min/1.73m², as it offers substantial cardiorenal protection 1, 4
The American College of Cardiology recommends considering a GLP-1 receptor agonist as additional therapy if glycemic targets are not met, due to its cardiovascular benefits and potential to prevent eGFR decline 1, 2, 5

The Endocrine Society recommends a target HbA1c of 7-8% for patients with moderate CKD, as more intensive targets increase the risk of hypoglycemia without clear mortality benefit 7
The American Journal of Kidney Diseases notes that the risk of hypoglycemia is increased in CKD due to decreased insulin clearance, impaired renal gluconeogenesis, and prolonged half-life of antihyperglycemic medications 6, 7, 9

The National Institute of Diabetes and Digestive and Kidney Diseases recommends regular blood glucose monitoring to detect hypoglycemia early, and HbA1c every 3 months until stable, then every 6 months 7, 9
The Kidney International journal recommends monitoring electrolytes, particularly if starting SGLT2 inhibitor, due to the risk of electrolyte imbalance 4

The American Heart Association recommends moderate-intensity physical activity for at least 150 minutes per week, and maintaining protein intake at approximately 0.8 g/kg/day 1, 2
The Academy of Nutrition and Dietetics recommends limiting sodium intake to <2 g/day, and avoiding excessive alcohol intake due to the increased risk of lactic acidosis with metformin 1, 2